Table 1.
Patient characteristics and treatment protocols
| Characteristic | n | PMRT
|
P-value | |
|---|---|---|---|---|
| None (%) | Yes (%) | |||
| Age (y) | ||||
| Median (range) | 221 | 32 (23–35) | 33 (20–35) | – |
| Tumor stage | ||||
| pT1 | 54 | 36 (66.7) | 18 (33.3) | 0.024 |
| pT2 | 134 | 81 (60.4) | 53 (39.6) | |
| pT3 | 23 | 7 (30.4) | 16 (69.6) | |
| pT4 | 10 | 5 (50.0) | 5 (50.0) | |
| Nodal stage | ||||
| pN1 | 116 | 92 (79.3) | 24 (20.7) | <0.001 |
| pN2 | 54 | 19 (35.2) | 35 (64.8) | |
| pN3 | 51 | 18 (35.3) | 33 (64.7) | |
| TNM stage | ||||
| II | 116 | 92 (79.3) | 24 (20.7) | <0.001 |
| III | 105 | 37 (35.2) | 68 (64.8) | |
| ER statusa | ||||
| Negative | 95 | 48 (50.5) | 47 (49.5) | 0.060 |
| Positive | 119 | 75 (63.0) | 44 (37.0) | |
| Unknown | 7 | 6 (85.7) | 1 (14.3) | |
| PR statusa | ||||
| Negative | 71 | 38 (53.5) | 33 (36.5) | 0.234 |
| Positive | 143 | 85 (59.4) | 58 (40.6) | |
| Unknown | 7 | 6 (85.7) | 1 (14.3) | |
| HER-2 statusb | ||||
| Negative | 129 | 78 (60.4) | 51 (39.6) | 0.181 |
| Positive | 71 | 36 (50.7) | 35 (49.3) | |
| Unknown | 21 | 15 (71.4) | 6 (28.6) | |
| Adjuvant chemotherapy regimen | ||||
| CMF | 24 | 16 (66.7) | 8 (33.3) | 0.383 |
| Anthracycline and/or taxane | 197 | 113 (57.4) | 84 (42.6) | |
Notes:
a
Positive status refers to 10% immuno-stained cells by immunohistochemical results.
b
Positive status refers to 3+ or 2+ score by immunohistochemical results that is confirmed to be positive by FISH test.
Abbreviations: CMF, cyclophosphamide, methotrexate, and 5-Fu; ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER-2, human epidermal growth factor receptor-2; PMRT, post-mastectomy radiotherapy; PR, progesterone receptor; TNM, tumor, lymph nodes, metastasis; 5-Fu, 5-fluorouracil.